{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T05:45:03Z","timestamp":1696398303523},"reference-count":22,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T00:00:00Z","timestamp":1427760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tenofovir disoproxil fumarate has been used in chronic hepatitis B patients with suboptimal virologic response to nucleos(t)ide analogues. The efficacy of tenofovir switch therapy has not been well studied in Asian patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the efficacy of tenofovir switch therapy in nucleos(t)ide\u2010experienced patients, and identify the factors associated with treatment response of tenofovir switch therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Nucleos(t)ide\u2010experienced hepatitis B e antigen\u2010positive and \u2010negative patients prescribed with tenofovir were retrospectively identified and recruited for prospective analysis. Hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> and other biochemical parameters were monitored in regular 3\u20136\u00a0monthly follow\u2010up visits. Primary efficacy endpoint was maintained\u2010virologic response with tenofovir switch therapy, defined as undetectable <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> (&lt;20\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL) until the last follow\u2010up visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>An overall of 214\/252 (84.9%) patients achieved maintained\u2010virologic response after 22 (7\u201355) months of tenofovir switch therapy. On multivariate analysis, a lower <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> level at the time of switching to tenofovir was an independent factor associated with treatment efficacy. Maintained\u2010virologic response after switching to tenofovir was achieved in 177\/190 (93.2%) patients with <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> &lt;20\u00a0000\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL vs. 37\/62 (59.7%) patients with <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> \u226520\u00a0000\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001). Absence of genotypic resistance to lamivudine or adefovir dipivoxil was not associated with improved treatment outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tenofovir switch therapy is an effective treatment strategy in nucleos(t)ide\u2010experienced chronic hepatitis B patients. However, in patients with <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> \u226520\u00a0000\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL at the time of switching to tenofovir, the chance of achieving maintained undetectable <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> is significantly reduced.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.13185","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:37:04Z","timestamp":1427848624000},"page":"1190-1199","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of tenofovir switch therapy for nucleos(t)ide\u2010experienced patients with chronic hepatitis B"],"prefix":"10.1111","volume":"41","author":[{"given":"A. O.\u2010S.","family":"Lo","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong"},{"name":"Institute of Digestive Disease The Chinese University of Hong Kong Hong Kong"},{"name":"State Key Laboratory of Digestive Disease The Chinese University of Hong Kong Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. W.\u2010S.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong"},{"name":"Institute of Digestive Disease The Chinese University of Hong Kong Hong Kong"},{"name":"State Key Laboratory of Digestive Disease The Chinese University of Hong Kong Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. L.\u2010H.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong"},{"name":"Institute of Digestive Disease The Chinese University of Hong Kong Hong Kong"},{"name":"State Key Laboratory of Digestive Disease The Chinese University of Hong Kong Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.\u2010K.","family":"Tse","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong"},{"name":"Institute of Digestive Disease The Chinese University of Hong Kong Hong Kong"},{"name":"State Key Laboratory of Digestive Disease The Chinese University of Hong Kong Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2010Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong"},{"name":"Institute of Digestive Disease The Chinese University of Hong Kong Hong Kong"},{"name":"State Key Laboratory of Digestive Disease The Chinese University of Hong Kong Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. L.\u2010Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong"},{"name":"Institute of Digestive Disease The Chinese University of Hong Kong Hong Kong"},{"name":"State Key Laboratory of Digestive Disease The Chinese University of Hong Kong Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,3,31]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-012-9365-4"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350501000612"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22790"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26686"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302024"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26301"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23246"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02600-12"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.223206"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.018"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01037.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10185"},{"key":"e_1_2_7_17_1","first-page":"S677A","article-title":"Tenofovir monotherapy in Asian chronic hepatitis B patients with genotypic resistance or partial virologic response to multiple previous antiviral therapies","volume":"58","author":"An J","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.024"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.044"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26277"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12629"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.053"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.079"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13185","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:04:18Z","timestamp":1695539058000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,31]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/apt.13185"],"URL":"https:\/\/doi.org\/10.1111\/apt.13185","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,31]]}}}